alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy.
D000328:Adult; D000368:Aged; D005340:Fibrinogen / Q000378:metabolism*; D005341:Fibrinolysin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D013300:Streptokinase / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin / Q000378:metabolism*; D000511:alpha-Macroglobulins
D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D000511:alpha-Macroglobulins; D005340:Fibrinogen; D013300:Streptokinase; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator